The ENCALM Trial: a Randomized, Double-blind, Placebo-controlled Monotherapy Trial to Evaluate the Efficacy and Safety of ENX-102 in Patients with Generalized Anxiety Disorder
Latest Information Update: 03 Sep 2024
At a glance
- Drugs ENX 102 (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Acronyms ENCALM
- Sponsors Engrail Therapeutics
- 30 Aug 2024 Planned number of patients changed from 200 to 280.
- 30 Aug 2024 Planned End Date changed from 1 Jun 2025 to 1 Dec 2025.
- 30 Aug 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.